Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early-stage testis cancer.

R S Foster1

  • 1Department of Urology, Indiana University Medical Center, 535 North Barnhill Drive, Suite 420, Indianapolis, IN 46224, USA. rsfoster@iupui.edu

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of QSAR models for predicting mutagenicity: outcome of the Second Ames/QSAR international challenge project.

SAR and QSAR in environmental research·2023
Same author

Commentary on "Prognostic effect of carcinoma in situ in muscle-invasive urothelial carcinoma patients receiving neoadjuvant chemotherapy."

Urologic oncology·2018
Same author

Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

What are the indications for postchemotherapy retroperitoneal lymph node dissection?

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

[Nerve sparing retroperitoneal lymphadenectomy (RLA)].

Aktuelle Urologie·2010
Same author

Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor.

Annals of oncology : official journal of the European Society for Medical Oncology·2010

Treatment for early-stage testis cancer, including seminoma and nonseminoma, offers several options. Choices depend on cancer type and stage, balancing effectiveness with treatment toxicity and recurrence risk for optimal outcomes.

Area of Science:

  • Oncology
  • Urologic Oncology
  • Medical Treatment Efficacy

Background:

  • Low-stage testis cancer (clinical stage I or low-volume II) management differs based on seminoma or nonseminoma histology.
  • Current treatment paradigms involve surgery, chemotherapy, radiotherapy, and surveillance, each with distinct toxicity profiles.
  • Balancing short-term cure rates with long-term sequelae is crucial in selecting optimal therapy.

Purpose of the Study:

  • To outline and compare therapeutic options for low-stage testicular germ cell tumors.
  • To evaluate the short-term efficacy and long-term considerations of various treatment modalities.
  • To inform clinical decision-making by presenting equivalent treatment strategies for early-stage testis cancer.

Main Methods:

  • Review of established treatment protocols for clinical stage I and low-volume II testicular cancer.

Related Experiment Videos

  • Comparison of treatment outcomes for seminoma and nonseminoma subtypes.
  • Consideration of factors including nerve-sparing retroperitoneal lymph node dissection (RPLND), surveillance, carboplatin, cisplatin-based chemotherapy, and BEP (bleomycin, etoposide, platinum) regimens.

    • Main Results:

    • For clinical stage I seminoma, radiotherapy, surveillance, and carboplatin show comparable short-term results; radiotherapy and surveillance are currently standard pending further data.
    • For non-bulky clinical stage II seminoma, radiotherapy or cisplatin-based chemotherapy are options.
    • For clinical stage I nonseminoma, nerve-sparing RPLND, surveillance, or BEP chemotherapy offer equivalent survival; RPLND or surveillance are preferred to minimize toxicity.
    • For low-volume clinical stage II nonseminoma, BEP chemotherapy or primary RPLND yield similar cure rates.

    Conclusions:

    • Therapeutically equivalent options exist for each stage of early-stage testis cancer based on current data.
    • The choice of treatment should prioritize minimizing short- and long-term toxicity and considering the risk of late recurrence.
    • Individualized treatment selection is paramount in managing low-stage testicular cancer.